1
|
Mohammed AD, Mohammed Z, Roland MM, Chatzistamou I, Jolly A, Schoettmer LM, Arroyo M, Kakar K, Tian Y, Patterson A, Nagarkatti M, Nagarkatti P, Kubinak JL. Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel. Nat Commun 2022; 13:525. [PMID: 35082296 PMCID: PMC8792037 DOI: 10.1038/s41467-022-28126-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Accepted: 01/04/2022] [Indexed: 12/13/2022] Open
Abstract
Mucosal antibodies maintain gut homeostasis by promoting spatial segregation between host tissues and luminal microbes. Whether and how mucosal antibody responses influence gut health through modulation of microbiota composition is unclear. Here, we use a CD19-/- mouse model of antibody-deficiency to demonstrate that a relationship exists between dysbiosis, defects in bile acid homeostasis, and gluten-sensitive enteropathy of the small intestine. The gluten-sensitive small intestine enteropathy that develops in CD19-/- mice is associated with alterations to luminal bile acid composition in the SI, marked by significant reductions in the abundance of conjugated bile acids. Manipulation of bile acid availability, adoptive transfer of functional B cells, and ablation of bacterial bile salt hydrolase activity all influence the severity of small intestine enteropathy in CD19-/- mice. Collectively, results from our experiments support a model whereby mucosal humoral immune responses limit inflammatory disease of the small bowel by regulating bacterial BA metabolism.
Collapse
Affiliation(s)
- Ahmed Dawood Mohammed
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA.,University of Baghdad School of Veterinary Medicine, Baghdad, Iraq
| | - Zahraa Mohammed
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA.,Al-Mustansiriyah University School of Medicine Department of Microbiology, Baghdad, Iraq
| | - Mary M Roland
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Ioulia Chatzistamou
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Amy Jolly
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Lillian M Schoettmer
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Mireya Arroyo
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Khadija Kakar
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Yuan Tian
- Pennsylvania State University Department of Veterinary and Biomedical Sciences, State College, PA, USA
| | - Andrew Patterson
- Pennsylvania State University Department of Veterinary and Biomedical Sciences, State College, PA, USA
| | - Mitzi Nagarkatti
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Prakash Nagarkatti
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA
| | - Jason L Kubinak
- University of South Carolina School of Medicine Department of Pathology, Microbiology, Immunology 6439 Garners Ferry Rd., Columbia, SC, 29209, USA.
| |
Collapse
|
2
|
Abstract
The normal indigenous intestinal microflora consists of about 10(15) bacteria that under physiological conditions reside mainly in the lower gastrointestinal tract. Bacterial overgrowth implies abnormal bacterial colonization of the upper gut, resulting from failure of specific defense mechanisms restricting colonization under physiological conditions. At present two types of bacterial overgrowth with defined pathogenesis can be distinguished: (1) gastric overgrowth with upper respiratory tract microflora resulting from selective failure of the gastric acid barrier, and (2) gastrointestinal overgrowth with Gram-negative bacilli (enteric bacteria) resulting from failure of intestinal clearance. Helicobacter pylori-induced gastritis of the oxyntic mucosa is the main cause of acquired failure of the gastric acid barrier, which is common among the healthy elderly. Intestinal clearance may fail as the result of impaired intestinal peristalsis or anatomical abnormalities that alter luminal flow. Impaired peristalsis is associated with conditions interfering with intestinal neuromuscular function including myopathic, neuropathic, autoimmune, infectious, inflammatory, metabolic, endocrine, and neoplastic diseases. Anatomical abnormalities are mainly the result of gastrointestinal surgery, intestinal diverticula or fistula. Combined failure of intestinal clearance and the gastric acid barrier results in more severe colonization with Gram-negative bacilli. Gram-negative bacilli are uncommon in the upper gut of otherwise healthy individuals with gastric hypochlorhydria, being acquired (H. pylori) or drug-induced. Significant bacterial overgrowth with Gram-negative bacilli is a rational in the search for an explanation to optimize clinical management. The clinical significance of colonization with upper respiratory tract microflora remains unclear. Translocation of live bacteria, their metabolic products, or antigens from a small bowel colonized by Gram-negative bacilli play a role in the pathogenesis of spontaneous bacterial peritonitis in hepatic disease and in certain types of sepsis, indicating that further studies can point to new patient populations with potential benefit from medical treatment.
Collapse
Affiliation(s)
- Einar Husebye
- Clinic of Medicine, Hospital of Buskerud HF, Drammen, and Division of Medicine, Ullevaal University Hospital of Oslo, Oslo, Norway.
| |
Collapse
|
3
|
Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998; 56:447-86. [PMID: 9777317 DOI: 10.2165/00003495-199856030-00012] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
UNLABELLED Omeprazole is a well studied proton pump inhibitor that reduces gastric acid secretion. This review examines its use in Helicobacter pylori infection, gastro-oesophageal reflux disease (GORD) with or without oesophagitis and gastrointestinal damage caused by nonsteroidal anti-inflammatory drugs (NSAIDs). Optimal omeprazole regimens for anti-H. pylori therapy are those that administer the drug at a dosage of 40 mg/day (in 1 or 2 divided doses) for 7, 10 or 14 days in combination with 2 antibacterial agents. As a component of 3-drug regimens in direct comparative studies, omeprazole was at least as effective as lansoprazole, pantoprazole, bismuth compounds and ranitidine. However, a meta-analysis suggests that triple therapies with omeprazole are more effective than comparable regimens containing ranitidine, lansoprazole or bismuth. Omeprazole also appears to be successful in triple therapy regimens used in children with H. pylori infection. In patients with acute GORD with oesophagitis, omeprazole is at least as effective as lansoprazole or pantoprazole in promoting healing, and superior to ranitidine, cimetidine or cisapride in oesophagitis healing and symptom relief. Omeprazole was similar to lansoprazole and superior to ranitidine in preventing oesophagitis relapse in patients with all grades of oesophagitis, but may be superior to lansoprazole or pantoprazole in patients with more severe disease. More patients with symptomatic GORD without oesophagitis experienced symptom relief after short term treatment with omeprazole than with ranitidine, cisapride or placebo, and symptoms were more readily prevented by omeprazole than by cimetidine or placebo. Omeprazole was effective in healing and relieving symptoms of reflux oesophagitis in children with oesophagitis refractory to histamine H2 receptor antagonists. Omeprazole is superior to placebo in preventing NSAID-induced gastrointestinal damage in patients who must continue to take NSAIDs. It is also similar to misoprostol and superior to ranitidine in its ability to heal NSAID-induced peptic ulcers and erosions, and superior to misoprostol, ranitidine or placebo in its ability to prevent relapse. In long and short term studies, omeprazole was well tolerated, with diarrhoea, headache, dizziness, flatulence, abdominal pain and constipation being the most commonly reported adverse events. Usual omeprazole dosages, alone or combined with other agents, are 10 to 40 mg/day for adults and 10 to 20 mg/day for children. CONCLUSIONS Omeprazole is a well studied and well tolerated agent effective in adults or children as a component in regimens aimed at eradicating H. pylori infections or as monotherapy in the treatment and prophylaxis of GORD with or without oesophagitis or NSAID-induced gastrointestinal damage.
Collapse
Affiliation(s)
- H D Langtry
- Adis International Limited, Auckland, New Zealand.
| | | |
Collapse
|